weightloss.com.au
Head-to-head comparison

Compare Saxenda vs. Ozempic

Saxenda (liraglutide) was discontinued in Australia in December 2025, while Ozempic (semaglutide) remains available for type 2 diabetes. Both are GLP-1 receptor agonists from Novo Nordisk, but Ozempic produced greater weight loss (~15% vs ~8%) with the convenience of weekly rather than daily injections. Patients previously on Saxenda are being directed to Wegovy as a replacement.

Saxenda was discontinued in Australia (December 2025)
Saxenda logo
Saxenda
Liraglutide 3mg
~8%
avg. weight loss
Discontinued
per month
Ozempic logo
Ozempic
Semaglutide 0.25-1mg
~15%
avg. weight loss
$32 PBS / $134 private
per month

Compare Saxenda vs Ozempic at a Glance

Drug class
Saxenda
GLP-1 receptor agonist
Ozempic
GLP-1 receptor agonist
How taken
Saxenda
Daily injection
Ozempic
Weekly injection
Avg. weight loss
Saxenda
~8%
Ozempic
~15%
First approved
Saxenda
2014 (FDA), 2016 (TGA)
Ozempic
2017 (FDA), 2019 (TGA)
AU cost/month
Saxenda
Discontinued
Ozempic
$32 PBS / $134 private
PBS status
Saxenda
N/A (discontinued)
Ozempic
Yes (diabetes only)
Prescription needed?
Saxenda
Yes
Ozempic
Yes
AU supply status
Saxenda
Discontinued Dec 2025
Ozempic
Constrained (improving)

Compare Saxenda vs Ozempic Cost in Australia

Saxenda
Discontinued
per month
Ozempic
$32–134
$32 PBS / $134 private
per month (PBS: Yes (diabetes only))

Private prescription cost per month in AUD.

Compare Saxenda vs Ozempic Weight Loss Efficacy

Saxenda
~8%
avg. weight loss (5-10%)
Ozempic
~15%
avg. weight loss (10-17%)

Saxenda Clinical Trials

SCALE Obesity

8% weight loss vs 2.6% placebo

56 weeksn=3,731

SCALE Maintenance

Maintained weight loss after initial diet

56 weeks

Ozempic Clinical Trials

SUSTAIN 1-12

5-7kg weight loss (diabetes population)

30-104 weeks

STEP 1 (higher dose)

14.9% body weight reduction

68 weeks

Clinical trial data at highest approved doses. Individual results vary.

Compare Saxenda vs Ozempic Side Effects

Saxenda

Very common

  • Nausea (39%)
  • Diarrhoea
  • Constipation
  • Vomiting

Common

  • Headache
  • Decreased appetite
  • Dyspepsia
  • Fatigue
  • Dizziness

Serious (rare)

  • Pancreatitis
  • Gallbladder disease
  • Increased heart rate
  • Thyroid tumour risk (animal data)
  • Acute kidney injury

Ozempic

Very common

  • Nausea (20-44%)
  • Diarrhoea (8-30%)
  • Vomiting

Common

  • Constipation
  • Abdominal pain
  • Headache
  • Fatigue
  • Injection site reactions

Serious (rare)

  • Pancreatitis
  • Gallbladder problems
  • Kidney injury
  • Thyroid tumours (animal studies)
  • Suicidal ideation (under investigation)

Compare How Saxenda and Ozempic Work

Saxenda

GLP-1 receptor agonist

First-generation GLP-1 receptor agonist for weight loss. Same mechanism as Ozempic/Wegovy (appetite reduction, slowed gastric emptying) but requires daily injection and produces less weight loss than semaglutide.

Ozempic

GLP-1 receptor agonist

Mimics the natural hormone GLP-1. Slows gastric emptying, increases insulin production, reduces glucagon, and acts on appetite centres in the brain to reduce hunger. Once-weekly injection in abdomen, thigh, or upper arm.

Compare Saxenda vs Ozempic Dosing Schedule

Saxenda

Daily injection

DosePeriodNote
0.6mgWeek 1Starting dose (daily)
1.2mgWeek 2Escalation
1.8mgWeek 3Escalation
2.4mgWeek 4Escalation
3mgWeek 5+Maintenance dose

Ozempic

Weekly subcutaneous injection

DosePeriodNote
0.25mgWeeks 1-4Starting dose
0.5mgWeeks 5-8Dose escalation
1mgWeek 9+Maintenance dose

Compare Saxenda vs Ozempic Australian Regulatory Status

Saxenda

TGA Status
Discontinued in Australia (December 2025)
PBS Listed
Never PBS listed for weight management
Replacement
Novo Nordisk directs patients to Wegovy
Historical Note
First GLP-1 approved for weight loss in Australia; now superseded

Ozempic

TGA Status
Registered on ARTG for type 2 diabetes
PBS Listed
Yes, for type 2 diabetes (Authority Required)
Off-label Use
Restricted since Oct 2024 for new weight loss prescriptions
Supply Status
Ongoing shortage since 2022; improving but not resolved
Compounding
Compounded versions banned from 1 October 2024

This website is for informational and research purposes only.

We are not medical professionals and nothing on this page constitutes medical advice, diagnosis, or treatment. Always consult a qualified doctor or specialist before making any decisions about medication.

The weight loss medication landscape in Australia is changing rapidly. Information on this page may become outdated without notice. Data sourced from the TGA, FDA, MHRA, NICE, PBAC, Australian Prescriber, Obesity Evidence Hub, and clinical trial publications. Last reviewed March 2026.